Close Menu

Imperial College London

The firm's EpiSwitch test for blood-based diagnosis of prostate cancer will be evaluated as part of the ongoing PROSTAGRAM trial.

The researchers also determined that the two most widely used IGRAs used for diagnosing the disease in developed countries are not accurate for active TB.

The UK developers believe that their device has the potential for multiplex testing at the point of care using solid-state nanopore sensing with DNA probes.

The initiative includes academic and private sector partners and aims to train new researchers in the early diagnosis of brain cancer.